Replimune Group Stock Performance
| REPL Stock | USD 13.26 1.67 11.19% |
On a scale of 0 to 100, Replimune holds a performance score of 7. The company holds a Beta of 1.74, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Replimune will likely underperform. Please check Replimune's value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Replimune's historical price patterns will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Replimune Group are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite quite unfluctuating basic indicators, Replimune disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 7.88 | Five Day Return 28.41 | Year To Date Return 64.99 | Ten Year Return (5.64) | All Time Return (5.64) |
1 | Insider Trading | 09/04/2024 |
2 | Stockholders Vote to Elect Madhavan Balachandran to Board of Directors | 09/05/2024 |
3 | Disposition of 5255 shares by Christopher Sarchi of Replimune at 10.92 subject to Rule 16b-3 | 09/20/2024 |
4 | Acquisition by Christopher Sarchi of 66675 shares of Replimune at 7.73 subject to Rule 16b-3 | 10/04/2024 |
5 | Morgan Stanleys Strategic Reduction in Replimune Group Inc Holdings - Yahoo Finance | 10/07/2024 |
6 | Replimune Announces Inducement Grants Under NasdaqListing Rule 5635 | 10/09/2024 |
7 | Acquisition by Jean Franchi of 67500 shares of Replimune at 17.66 subject to Rule 16b-3 | 11/01/2024 |
8 | Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 11/08/2024 |
9 | Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update | 11/12/2024 |
10 | Disposition of 5207 shares by Christopher Sarchi of Replimune at 10.78 subject to Rule 16b-3 | 11/18/2024 |
11 | Replimunes chief commercial officer sells 56,131 in stock | 11/21/2024 |
12 | Replimune stock target lifted, outperform on BLA submission | 11/22/2024 |
13 | Replimune Announces Proposed Public Offering | 11/25/2024 |
| Begin Period Cash Flow | 148.2 M |
Replimune |
Replimune Relative Risk vs. Return Landscape
If you would invest 1,030 in Replimune Group on August 28, 2024 and sell it today you would earn a total of 296.00 from holding Replimune Group or generate 28.74% return on investment over 90 days. Replimune Group is currently generating 0.5418% in daily expected returns and assumes 5.7571% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Replimune, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Replimune Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Replimune's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Replimune Group, and traders can use it to determine the average amount a Replimune's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0941
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | REPL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.76 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.54 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Replimune is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Replimune by adding it to a well-diversified portfolio.
Replimune Fundamentals Growth
Replimune Stock prices reflect investors' perceptions of the future prospects and financial health of Replimune, and Replimune fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Replimune Stock performance.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 551.28 M | ||||
| Shares Outstanding | 68.42 M | ||||
| Price To Book | 2.68 X | ||||
| EBITDA | (230.2 M) | ||||
| Net Income | (215.79 M) | ||||
| Cash And Equivalents | 395.08 M | ||||
| Cash Per Share | 8.01 X | ||||
| Total Debt | 75.87 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 19.79 X | ||||
| Book Value Per Share | 5.58 X | ||||
| Cash Flow From Operations | (185.47 M) | ||||
| Earnings Per Share | (3.04) X | ||||
| Market Capitalization | 907.21 M | ||||
| Total Asset | 487.72 M | ||||
| Retained Earnings | (701.28 M) | ||||
| Working Capital | 393.23 M | ||||
About Replimune Performance
By examining Replimune's fundamental ratios, stakeholders can obtain critical insights into Replimune's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Replimune is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.52) | (0.55) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.58) | (0.55) |
Things to note about Replimune Group performance evaluation
Checking the ongoing alerts about Replimune for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Replimune Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Replimune Group is way too risky over 90 days horizon | |
| Replimune Group appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (215.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Replimune Group currently holds about 395.08 M in cash with (185.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.01. | |
| Replimune Group has a poor financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Replimune Announces Proposed Public Offering |
- Analyzing Replimune's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Replimune's stock is overvalued or undervalued compared to its peers.
- Examining Replimune's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Replimune's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Replimune's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Replimune's stock. These opinions can provide insight into Replimune's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.